Antiphospholipid syndrome

Hematology Journal

Volumn 5, Issue SUPPL. 3, 2004, Pages

  Arnout, Jef ^a   Jankowski, Milosz ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; PROTHROMBIN;

ANTICOAGULATION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BINDING AFFINITY; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOASSAY; IN VITRO STUDY; LABORATORY DIAGNOSIS; PATHOGENESIS; PREGNANCY COMPLICATION; THROMBOGENESIS; THROMBOSIS;

EID: 4043140023     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200412     Document Type: Article

References (20)

1. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003; 1: 931-942.
2. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta-2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124.
3. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547.
4. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. 'Anticardiolip' in autoantibodies recognize 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995; 154: 954-960.
5. Lechner K. A new type of coagulation inhibitor. Thromb Diath Haemorrh 1969; 21: 482-499.
6. Willems GM, Janssen MP, Pelsers MMAL, Comfurius P, Galli M, Zwaal RFA et al. Role of divalency in the high-affinity binding of anticardiolipin antibody-2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833-13842.
7. Takeya, H, Mori T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E et al. Anti-2-glycoprotein I(2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the 2GPI binding to phospholipids. J Clin Invest 1997; 99: 2260-2268.
8. Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent, antibody-beta-2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost 1998; 79: 79-86.
9. Lutters BC, Meijers JC, Derksen RH, Arnout J, de Groot PG. Dimers of beta 2-glycoprotein I mimic the in vitro effects of beta 2-glycoprotein I-anti-beta 2-glycoprotein I antibody complexes. J Biol 2001; 276: 3060-3067.
10. Field SL, Chesterman CN, Dai YP, Hogg PJ. Lupus antibody bivalency is required to enhance prothrombin binding to phospholipid. J Immunol 2001; 166: 6118-6125.
11. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
12. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001; 86: 83-91.
13. Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus 2002; 11: 269-275.
14. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome. A systematic review of the literature. Blood 2003; 101: 1827-1832.
15. Simmelink MJA, Derksen RHWM, Arnout J, de Groot PG. A simple method to discriminate between 2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003; 1: 740-747.
16. Safa O, Hensley K, Smirnov MD, Esmon CT, Esmon NL. Lipid oxidation enhances the function of activated protein C. J Biol Chem 2001; 276: 1829-1836.
17. Jankowski M, Vreys I, Wittevrongel C, Boon D, Vermylen J, Hoylaerts MF et al. Thrombogenicity of beta-2-glycoprotein I dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101: 157-162.
18. Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, De Groot PG. Dimers of 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003; 278: 33831-33838.
19. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119 (Suppl 1): 176S-193S.
20. Finazzi G, Marchioli R, Barbui T. A randomized clinical trial of oral anticoagulant therapy in patients with the antiphospholipid syndrome: the WAPS study. J Thromb Haemost 2003; 1 (Suppl 1): Abst OC365.